Changes in Study Status and Arms and Interventions With Illuminate-301 ... | IDRA Message Board Posts

Idera Pharmaceuticals, Inc

  IDRA website

IDRA   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  1447 of 1565  at  6/18/2019 8:46:31 AM  by

raferjack


 In response to msg 1445 by  auh2oman
view thread

Re: Changes in Study Status and Arms and Interventions With Illuminate-301 ...

 Good pickup.
I had not realized that they had changed the phase 3 ipi administration to week 1,4,7,10.
By my reading it is now week 2,5,8,11 as it has been in prior studies including phase 1/2.
My suspicion is that they are seeing it takes a little more time for Tilso to prime the immune microenvironment so starting at week 2 (as before) is a better fit. It is something they are likely seeing on the translational data. I hope this is just tweaking the protocol rather than less impressive findings the way it was set up for phase 3. I guess it could always be some logistic reason as well.  


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 3     Views: 166
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
1448 Re: Changes in Study Status and Arms and Interventions With Illuminate-301 ... auh2oman 2 6/18/2019 9:50:24 AM
1450 Re: Changes in Study Status and Arms and Interventions With Illuminate-301 ... cert77 1 6/18/2019 12:37:13 PM
1458 Re: Changes in Study Status and Arms and Interventions With Illuminate-301 ... vorlon1966 1 6/24/2019 3:52:11 PM






About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.


Loading...